Cirio advises Intervacc AB (publ) in connection with a rights issue

Cirio advises Intervacc AB (publ) in connection with its fully secured rights issue of shares. The board of directors of Intervacc resolved, based on the authorization from an extraordinary general meeting, on the rights issue on 11 May 2023. Intervacc will receive a total proceeds of approximately SEK 100 million, before issue costs.

Intervacc AB (publ) is a company within animal health developing vaccines for animals. The company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research. The company’s share is listed on Nasdaq First North Growth Market.

Cirio advised Intervacc AB (publ) with a team headed by Maria Arnoldsson (Capital Markets and Public M&A) and Per Hedman (Life sciences), together with Louise Åberg and Fredrik Billing (Capital Markets and Public M&A).